Mosley Wealth Management Purchases 105 Shares of Novartis AG (NYSE:NVS)

Mosley Wealth Management raised its position in Novartis AG (NYSE:NVS) by 4.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,238 shares of the company’s stock after acquiring an additional 105 shares during the period. Mosley Wealth Management’s holdings in Novartis were worth $238,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of NVS. Founders Financial Securities LLC increased its holdings in shares of Novartis by 3.4% in the second quarter. Founders Financial Securities LLC now owns 2,832 shares of the company’s stock valued at $301,000 after purchasing an additional 94 shares during the last quarter. NBC Securities Inc. raised its holdings in shares of Novartis by 0.9% during the 2nd quarter. NBC Securities Inc. now owns 10,492 shares of the company’s stock worth $1,116,000 after acquiring an additional 97 shares during the period. EverSource Wealth Advisors LLC boosted its position in shares of Novartis by 5.1% during the 1st quarter. EverSource Wealth Advisors LLC now owns 2,013 shares of the company’s stock valued at $196,000 after acquiring an additional 98 shares during the last quarter. Portside Wealth Group LLC boosted its position in shares of Novartis by 3.4% during the 2nd quarter. Portside Wealth Group LLC now owns 3,000 shares of the company’s stock valued at $319,000 after acquiring an additional 99 shares during the last quarter. Finally, Evermay Wealth Management LLC grew its holdings in shares of Novartis by 9.3% in the first quarter. Evermay Wealth Management LLC now owns 1,176 shares of the company’s stock valued at $114,000 after purchasing an additional 100 shares during the period. 13.12% of the stock is owned by hedge funds and other institutional investors.

Novartis Trading Up 0.1 %

Novartis stock traded up $0.16 during midday trading on Friday, reaching $116.65. 1,151,373 shares of the stock traded hands, compared to its average volume of 1,407,379. The firm has a market cap of $238.43 billion, a PE ratio of 15.75, a price-to-earnings-growth ratio of 1.77 and a beta of 0.57. The company has a current ratio of 0.93, a quick ratio of 0.72 and a debt-to-equity ratio of 0.47. The company has a 50-day simple moving average of $112.66 and a two-hundred day simple moving average of $104.51. Novartis AG has a 12-month low of $92.19 and a 12-month high of $120.92.

Novartis (NYSE:NVS) last posted its quarterly earnings data on Thursday, July 18th. The company reported $1.97 EPS for the quarter, beating the consensus estimate of $1.87 by $0.10. Novartis had a net margin of 33.76% and a return on equity of 34.56%. The business had revenue of $12.87 billion during the quarter, compared to analyst estimates of $12.24 billion. During the same quarter last year, the firm posted $1.83 earnings per share. Research analysts expect that Novartis AG will post 7.48 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on NVS shares. The Goldman Sachs Group reiterated a “neutral” rating and issued a $121.00 target price (up from $119.00) on shares of Novartis in a report on Thursday. Jefferies Financial Group cut Novartis from a “buy” rating to a “hold” rating in a research note on Tuesday. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Novartis in a research note on Friday, July 19th. Finally, Barclays upgraded shares of Novartis to a “strong sell” rating in a report on Monday, June 24th. One analyst has rated the stock with a sell rating, six have issued a hold rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $118.38.

Novartis Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.